Creotech Instruments S.A.
Creotech Instruments S.A. operates in the space and science industry in Poland. The company produces aircrafts, spacecrafts, electronic components, computers and peripheral devices, telecommunications equipment, and related machines. It also manufactures measuring, control, and navigation instruments and devices; produces and distributes electricity; and produces control apparatus. In addition, t… Read more
Creotech Instruments S.A. (CRI) - Net Assets
Latest net assets as of September 2025: zł140.72 Million PLN
Based on the latest financial reports, Creotech Instruments S.A. (CRI) has net assets worth zł140.72 Million PLN as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł316.96 Million) and total liabilities (zł176.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł140.72 Million |
| % of Total Assets | 44.4% |
| Annual Growth Rate | 67.23% |
| 5-Year Change | 886.1% |
| 10-Year Change | N/A |
| Growth Volatility | 71.37 |
Creotech Instruments S.A. - Net Assets Trend (2019–2024)
This chart illustrates how Creotech Instruments S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Creotech Instruments S.A. (2019–2024)
The table below shows the annual net assets of Creotech Instruments S.A. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł70.95 Million | -22.35% |
| 2023-12-31 | zł91.37 Million | +88.56% |
| 2022-12-31 | zł48.46 Million | +166.24% |
| 2021-12-31 | zł18.20 Million | +152.95% |
| 2020-12-31 | zł7.20 Million | +32.76% |
| 2019-12-31 | zł5.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Creotech Instruments S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1815247400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł238.00K | 0.34% |
| Other Components | zł92.19 Million | 129.93% |
| Total Equity | zł70.95 Million | 100.00% |
Creotech Instruments S.A. Competitors by Market Cap
The table below lists competitors of Creotech Instruments S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eventbrite Inc
F:EB4
|
$272.86 Million |
|
Community Health Systems Inc
NYSE:CYH
|
$272.88 Million |
|
Shaanxi Kanghui Pharm Co Ltd
SHG:603139
|
$272.90 Million |
|
STECON GROUP NON-VOTING DR PCL
BK:STECON
|
$272.91 Million |
|
Jiangsu Phoenix Property Investment Co Ltd
SHG:600716
|
$272.79 Million |
|
Dream Unlimited Corp
PINK:DRUNF
|
$272.77 Million |
|
Médica Sur S.A.B. de C.V
MX:MEDICAB
|
$272.64 Million |
|
Zhejiang Meida Industrial Co Ltd
SHE:002677
|
$272.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Creotech Instruments S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 91,371,000 to 70,954,000, a change of -20,417,000 (-22.3%).
- Net loss of 20,455,000 reduced equity.
- Other comprehensive income decreased equity by 146,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-20.45 Million | -28.83% |
| Other Comprehensive Income | zł-146.00K | -0.21% |
| Other Changes | zł184.00K | +0.26% |
| Total Change | zł- | -22.35% |
Book Value vs Market Value Analysis
This analysis compares Creotech Instruments S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 23.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 206.04x to 23.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | zł3.42 | zł704.00 | x |
| 2020-12-31 | zł4.54 | zł704.00 | x |
| 2021-12-31 | zł11.47 | zł704.00 | x |
| 2022-12-31 | zł24.44 | zł704.00 | x |
| 2023-12-31 | zł38.40 | zł704.00 | x |
| 2024-12-31 | zł29.83 | zł704.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Creotech Instruments S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -79.59%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 2.29x
- Recent ROE (-28.83%) is below the historical average (-4.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 4.71% | 1.00% | 1.20x | 3.95x | zł-286.63K |
| 2020 | 24.68% | 6.07% | 0.95x | 4.28x | zł1.06 Million |
| 2021 | 2.61% | 1.44% | 0.72x | 2.53x | zł-1.35 Million |
| 2022 | -14.51% | -34.79% | 0.26x | 1.58x | zł-11.88 Million |
| 2023 | -15.70% | -46.68% | 0.18x | 1.89x | zł-23.48 Million |
| 2024 | -28.83% | -79.59% | 0.16x | 2.29x | zł-27.55 Million |
Industry Comparison
This section compares Creotech Instruments S.A.'s net assets metrics with peer companies in the Aerospace & Defense industry.
No peer company data available for comparison.